News from ucb A wide array of domestic and global news stories; news topics include politics/government, business, technology, religion, sports/entertainment, science/nature, and health/lifestyle. Articles that appear in this section may be written in English or other languages

Latest

Jul 11, 2018, 08:00 ET UCB Launches the Autoimmune Motherhood (AIM) Movement™ to Empower and Inform Women with Chronic Inflammatory Disease About Family Planning

UCB, a global biopharmaceutical company, today announced the launch of the Autoimmune Motherhood (AIM) Movement to support women living with chronic...


Jul 02, 2018, 12:30 ET UCB Announces Approval of NEUPRO® in China to Treat Parkinson's Disease

NEUPRO now approved in China for the treatment of the signs and symptoms of early-stage idiopathic Parkinson's Disease as monotherapy (i.e. without...


Jun 15, 2018, 01:00 ET New Study Presented at the Annual European Congress of Rheumatology (EULAR 2018) Reveals Insights About Women with Chronic Rheumatic Diseases During Their Pregnancy Journey

UCB, a global biopharmaceutical company focusing on immunology, neurology and bone treatment and research, today presents findings from a patient...


May 29, 2018, 08:00 ET UCB Announces the Approval of CIMZIA® (certolizumab pegol) for Moderate-to-Severe Plaque Psoriasis, Representing an Important New Option for Patients in the U.S.

The U.S. Food and Drug Administration's (FDA) approval of CIMZIA® (certolizumab pegol) for use in moderate-to-severe plaque psoriasis marks the entry ...


May 16, 2018, 04:02 ET CIMZIA® (certolizumab pegol) is the First Therapy to Demonstrate Positive Results in a 52-week, Placebo Controlled Non-Radiographic Axial Spondyloarthritis Study

Positive top line results from Phase 3 C-AXSPAND study underscore the potential of CIMZIA® (certolizumab pegol) for non-radiographic axial...


May 14, 2018, 08:00 ET UCB Announces BRIVIACT® (Brivaracetam) now Approved by FDA to Treat Partial-onset (Focal) Seizures in Pediatric Epilepsy Patients

- BRIVIACT® (brivaracetam) CV oral formulations are approved as a monotherapy or adjunctive therapy in patients four years of age and older with...


Apr 05, 2018, 07:00 ET UCB Strengthens Research Capabilities With Acquisition of Element Genomics, a Duke University Biotech Spin-off

UCB announces the acquisition of Element Genomics, a small-size biotech spin-off from Duke University, based in Durham, North Carolina (USA). The...


Mar 22, 2018, 08:00 ET CIMZIA® (certolizumab pegol) label update marks major advance for women of childbearing age with chronic inflammatory disease in the U.S.

U.S. Food and Drug Administration (FDA) approves label change for UCB's CIMZIA® (certolizumab pegol) Data added to the label includes...


Feb 16, 2018, 10:08 ET UCB Advances Psoriasis Pipeline with Positive Data at American Academy of Dermatology Annual Meeting (AAD 2018)

UCB, a global biopharmaceutical company, will be presenting new data on CIMZIA® (certolizumab pegol) and one of UCB's key pipeline molecules,...


Jan 09, 2018, 01:00 ET CIMZIA® (certolizumab pegol) Label Change Marks Important Advance for European Women of Childbearing Age With Chronic Rheumatic Disease

European Medicines Agency (EMA) has approved label change for UCB's CIMZIA® (certolizumab pegol), making it the first anti-TNF for potential use in...


Nov 06, 2017, 08:00 ET UCB Presents New Findings Advancing Patient Care for Chronic Inflammatory Diseases and Osteoporosis at 2017 ACR/ARHP Annual Meeting

Key data focus on inflammatory and osteoporosis in patient populations with unmet needs including women of childbearing age and others: The results...


Nov 06, 2017, 07:00 ET UCB's VIMPAT® (lacosamide) now approved by FDA to treat partial-onset seizures in pediatric epilepsy patients

VIMPAT® (lacosamide) CV oral formulations are approved as a monotherapy or adjunctive therapy in patients four years of age and older with...


Sep 15, 2017, 01:00 ET New indication for BRIVIACT® (brivaracetam): UCB's newest antiepileptic drug approved by FDA as monotherapy treatment of partial-onset seizures in adults

UCB announced today that the U.S. Food and Drug Administration (FDA) has approved a supplemental new drug application (sNDA) for BRIVIACT®...


Jun 13, 2017, 18:01 ET Results from CRIB study on CIMZIA® (certolizumab pegol) demonstrate minimal to no placental transfer of drug from mother to infant during third trimester of pregnancy

UCB today presented results from CRIB, a pharmacokinetic study designed to assess if CIMZIA® (certolizumab pegol) is transferred across the placenta...


Apr 21, 2017, 12:30 ET UCB showcases latest epilepsy research at 2017 Annual Meeting of the American Academy of Neurology

UCB is pleased to announce that 12 scientific abstracts have been accepted for presentation at the upcoming Annual Meeting of the American Academy of ...


Mar 15, 2017, 07:00 ET UCB Launches Wellness 4U, an Innovative and Comprehensive Health and Wellness Program for Patients with Immunologic Diseases

UCB, a global biopharmaceutical company focusing on immunology, neurology and bone treatments and research, has launched Wellness 4U™, an...


Mar 06, 2017, 00:00 ET First CIMZIA® (certolizumab pegol) Study of Its Kind Showed Minimal to No Transfer of Drug from Mother's Plasma to Breast Milk

Today UCB announced results from the CRADLE study, the first lactation study designed to evaluate CIMZIA® (certolizumab pegol) concentrations in...


Jan 19, 2017, 11:00 ET UCB files BRIVIACT® (brivaracetam) CV in the U.S. as monotherapy treatment for adult epilepsy patients with partial-onset seizures

UCB has today announced the filing of a supplemental New Drug Application (sNDA) to the U.S. Food and Drug Administration (FDA) for BRIVIACT®...


Nov 15, 2016, 11:00 ET The Lancet Publishes First Head-to-Head Study of CIMZIA® (certolizumab pegol) and Humira® (adalimumab) in Bio-Naïve Rheumatoid Arthritis Patients

Today UCB announced that The Lancet published full results from EXXELERATE, the first head-to-head superiority study of two treatments in the...


Nov 11, 2016, 07:00 ET UCB showcases advancements in its late stage immunology portfolio through innovative research at 2016 ACR/ARHP Annual Meeting

UCB, a global biopharmaceutical company focusing on immunology, neurology and bone treatments and research, is proud to announce 16 CIMZIA®...


Nov 10, 2016, 08:00 ET UCB Family Epilepsy Scholarship Program™ Announces 2016 Recipients

UCB, Inc. today announced 40 recipients of the 2016 UCB Family Epilepsy Scholarship, recognizing outstanding individuals affected by epilepsy who are ...


Oct 24, 2016, 07:01 ET Certolizumab pegol (Cimzia®) AutoClicks® Prefilled Pen - a New Self-injection Device Designed in Collaboration With Patients and Good Grips® - is Now Available in the UK on the NHS[1]

UCB leads collaboration to design a prefilled pen for patients with rheumatic diseases Prefilled Pen designed for ease of use during self-injection...


Feb 19, 2016, 12:42 ET U.S. FDA approves UCB's new epilepsy treatment, BRIVIACT®, for patients with partial-onset seizures

Today UCB announced that the U.S. Food and Drug Administration (FDA) has approved BRIVIACT® (brivaracetam) as adjunctive therapy (a therapy used...


Dec 04, 2015, 01:00 ET UCB reinforces its commitment to epilepsy research with a strong presence at the 2015 American Epilepsy Society annual meeting

UCB is pleased to announce that 19 scientific abstracts have been accepted for poster presentation at the upcoming 69th American Epilepsy Society...


Nov 06, 2015, 09:00 ET UCB Presents Latest Research from Immunology Portfolio at American College of Rheumatology Annual Meeting

UCB, a global biopharmaceutical company focusing on immunology and neurology treatment and research, is presenting 19 studies of CIMZIA®...